Allogeneic NK cell injection
/ BOE Technology Group
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 27, 2026
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=42 | Not yet recruiting | Sponsor: BOE Technology Group Co., Ltd. | N=20 ➔ 42
Enrollment change • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hepatocellular Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • HER-2 • KRAS • ROS1
August 26, 2026
NK Cell Injection for Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=9 | Not yet recruiting | Sponsor: BOE Technology Group Co., Ltd.
New P1 trial • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1